Indian Type 1 Diabetes Mellitus Drugs market size stood at USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the
The incidence and prevalence of Type 1 diabetes (T1D) is considered to be high in India. Type 1 Diabetes Mellitus is a chronic disease caused by improper production of or the response to insulin in the body which causes high blood sugar levels. In order to control the damage which might be caused by the increasing cases of Type 1 diabetes mellitus in the country, the Indian Government is taking initiatives to provide free treatment and insulin to type 1 diabetics at government hospitals. The glucose monitoring devices segment is expected to exhibit the highest growth on account of increasing diabetic cases. The self-monitoring devices are still dominating the market because they are relatively easier to use and cheaper. The Indian Council of Medical Research funded Registry of People with diabetes in India with young age at onset (YDR) was started in the year 2006 with 10 collaborating centres across India.
The heightening obesity rates, rising stress levels, lack of proper exercise, adoption of sedentary lifestyle, increase in consumption of unhealthy diet, increase in the healthcare expenditures, growing prevalence of type 1 diabetes mellitus, increased demand of therapeutic drugs, the market for type 1 diabetes mellitus drugs and diagnostics is expanding robustly in India. In order to control the damage caused by the increasing cases of type 1 diabetes mellitus in the country, the Indian Government is taking initiatives to provide free treatment and insulin to diabetics at government hospitals. Some of the other factors contributing to the market growth are rapid urbanisation, developing healthcare infrastructure, low-cost of drug production, accelerating pharmaceutical contract manufacturing and introduction of advanced technologies.